Marie Obien

MaxWell Monthly Must-Reads (March 2018)

Today, we are launching a new blog series called MaxWell Monthly Must-Reads. Every month, we will feature interesting articles related to neuroscience, stem cell technology, drug discovery, and safety pharmacology. In this edition, we focus on Methods. We value well-designed experimental methods and protocols because they are key to new discoveries and ground-breaking results. Here, we include recent techniques for the generation of functionally active iPSC-derived neurons and brain organoids. We also feature a new single cell manipulation technique called…

Read More

10 Years Venture Kick Ceremony | MaxWell Biosystems is a Global Shaper

MaxWell Biosystems joined the celebration of Venture Kick’s 10-year anniversary last 29 November 2017. Held in Schlieren, the ceremony welcomed 500 guests–all involved in the Swiss innovation, entrepreneurship, and investment community. Venture Kick included a variety of events during the evening, such as a startup exhibition, speeches, guitar concert, and a fashion show. Everyone enjoyed the sumptuous dinner, desserts, and drinks. Global Shapers Venture Kick nominated high-impact startups for each of the ten years since the program started. The Global…

Read More

MaxWell Biosystems wins Venture Kick

MaxWell Biosystems passes the final stage of Venture Kick and wins CHF 100’000. After presenting at the final stage, MaxWell Biosystems convinced the Venture Kick jury and secured CHF 100’000, in addition to CHF 30’000 already granted in previous stages. Venture Kick supports the first steps of the realization of a business idea and awards selected start-ups with up to CHF 130’000 seed money. The final stage serves as the culmination of the year-long journey of MaxWell Biosystems with Venture Kick. The journey started last July…

Read More

MaxWell Biosystems featured in ETH News

MaxWell Biosystems gets more media coverage. ETH Zurich News features the spin-off company MaxWell Biosystems. The article highlights the company’s core technology developed in Hierlemann Lab (D-BSSE) and the motivation to commercialize thanks to the demand of induced pluripotent stem cell boom. Link to English version >> Link to German version >>

Read More

Retina study utilizing HD-MEAs (MaxOne) selected as “Best of Neuron”

The paper by K. Yonehara*, M. Fiscella*, A. Drinnenberg*, et al. entitled “Congenital Nystagmus Gene FRMD7 is necessary for establishing a neuronal circuit asymmetry for direction selectivity” was chosen for the “Best of Neuron” selection 2015-2016. “Best of Neuron“ includes ground-breaking neuroscience research published in Neuron and is a collection of editors’ and readers’ favorites. MaxWell Biosystems HD-MEA core technology was used in this study, to characterize the disease phenotype discovered in the FRMD7 mutant retina. Mutation in the FRMD7 gene is linked to the…

Read More
Contacts










Albisriederstrasse 253
8047 Zurich, Switzerland

+41 44 244 24 24

Schedule a call

info@mxwbio.com

Subscribe to our Newsletter